Alcohol-associated hepatitis (AH) remains a high-mortality condition with limited effective therapies. A central driver of disease progression is excessive hepatic inflammation, particularly massive neutrophil infiltration, triggered by cytokine signaling, chemokine release (e.
Alcohol-associated hepatitis (AH) remains a high-mortality condition with limited effective therapies. A central driver of disease progression is excessive hepatic inflammation, particularly massive neutrophil infiltration, triggered by cytokine signaling, chemokine release (e.g., CXCL1, CXCL8), endothelial activation, and sterile inflammation mediated by damage-associated molecular patterns such as HMGB1 and mitochondrial DNA.
This article highlights a newly described LECT2–PHB2 molecular axis as a mechanistic contributor to inflammatory amplification in AH. Leukocyte cell–derived chemotaxin 2 (LECT2), a hepatokine previously implicated in metabolic and inflammatory liver diseases, appears to interact with prohibitin-2 (PHB2), a mitochondrial and signaling regulator protein. Emerging data suggest that dysregulation of this pathway exacerbates hepatocellular stress responses, enhances inflammatory signaling, and promotes neutrophil recruitment, thereby worsening liver injury.
Importantly, the LECT2–PHB2 interaction may represent a novel therapeutic opportunity. Targeting this axis could interrupt the self-sustaining loop of hepatocyte injury and immune activation that characterizes severe AH. Given the limited efficacy of current treatments—largely restricted to corticosteroids in selected patients—identifying pathways that modulate both hepatocellular stress and inflammatory amplification is clinically significant.
In summary, the LECT2–PHB2 axis provides fresh mechanistic insight into AH pathogenesis and may offer a promising target for future drug development aimed at reducing inflammation and improving outcomes in this devastating condition.
Introduction: Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary liver cancer with poor prognosis and limited treatment options. While ICC has traditionally been considered a malignancy of biliary epithelial cells, increasing evidence suggests that hepatocytes can...
Introduction: Liver fibrosis is the key determinant of long-term outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Activated hepatic stellate cells (HSCs) drive fibrogenesis, but effective antifibrotic therapies remain unavailable. This study investigated whether blocking the succinate–GPR91...
Introduction: The progression from metabolic dysfunction-associated fatty liver (MAFL) to metabolic dysfunction-associated steatohepatitis (MASH) is driven by complex interactions between hepatocytes and immune cells. This study identifies a novel spatial mechanism in the periportal (PP)...
Introduction: Cardiovascular–Kidney–Metabolic (CKM) syndrome recognizes the close interaction between obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. This review highlights the emerging role of the gut microbiome, particularly butyrate-producing bacteria, as a central...
• Small intestinal adenocarcinoma (SIA) is a rare gastrointestinal cancer with limited disease-specific prognostic biomarkers and generally poor outcomes. • This nationwide Dutch population-based study evaluated whether three routinely available immunohistochemical markers—CK7, CK20, and CDX2—have...
Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely linked to insulin resistance and type 2 diabetes, with the liver traditionally viewed as a key regulator of blood glucose through hepatic glucose production. However, emerging...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.